Navigation Links
Step in breakdown of HIV proteins essential to recognition, destruction of infected cells
Date:5/9/2011

A key step in the processing of HIV within cells appears to affect how effectively the immune system's killer T cells can recognize and destroy infected cells. Researchers at the Ragon Institute of MGH, MIT and Harvard have found that as HIV proteins are broken down within cells, a process that should lead to labeling infected cell for destruction by CD8 T cells there is a great variability in the stability of resulting protein segments, variations that could significantly change how well cells are recognized by the immune system. Their report appears in the June Journal of Clinical Investigation.

"We have identified a novel mechanism by which HIV escapes recognition by virus-specific cytotoxic T cells, says Sylvie Le Gall, PhD, of the Ragon Institute, the paper's senior author. "This discovery may help us better understand the immune-system failure that characterizes HIV infection and provide information critical to the successful development of immune-system-based therapies."

CD8 T cells that have been programmed to target and destroy HIV-infected cells recognize those cells through tiny bits of viral protein, called peptides, displayed on the cell surface. Details of how HIV proteins are broken down into peptides and loaded onto the specialized molecules, called MHC Class I, that carry them to the cell surface are not well understood. Also unknown is whether particular HIV peptides are more effective than others in flagging cells for destruction.

Le Gall and her team first discovered that HIV peptides reduced to a length of 8 to 11 amino acids within infected cells varied greatly in their stability, with some breaking down further within seconds and others remaining unchanged for nearly an hour. Collaborators David Heckerman, MD, PhD, and Carl Kadie from Microsoft Research analyzed the biochemical features of 166 HIV peptides and identified particular structural patterns associated with either stability or instability. The researchers then showed that substituting a stability-associated structural motif for an instability motif significantly increased peptide stability, and vice-versa.

The stability of a peptide within the cell can significantly affect how much peptide is available to be loaded onto MHC Class I molecules and displayed on the cell surface. The authors found that several known HIV mutations significantly reduced peptide stability one common mutation virtually abolished the cell-killing action of CD8 T cells. The Microsoft team members have developed a model to predict the probable stability of specific HIV peptides, but more research is needed to determine how variations in stability affect the presentation of the peptide segments called epitopes to CD8 cells and whether changes in peptide stability lead to a more efficient immune response.

"Efforts to develop T-cell-based vaccines need to focus on producing epitopes that elicit the most protective response," says Le Gall, an assistant professor of Medicine at Harvard Medical School. "Modulating peptide stability offers a unique way of regulating epitope presentation in favor of producing the most effective defence against HIV."


'/>"/>

Contact: Sarah Dionne
smdionne@partners.org
617-726-6126
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Discovery of relationship between proteins may impact development of cancer therapies
2. Pitt-Stanford research suggests aimless proteins crucial to disease
3. 2 proteins play key roles in Burkitts lymphoma
4. Scripps Research scientists develop powerful new methodology for stabilizing proteins
5. Communication pathways within proteins may yield new drug targets to stop superbugs
6. Scripps Research scientists identify first synthetic activator of 2 critical proteins
7. Scientists at IRB Barcelona and BSC publish the worlds largest video data bank of proteins
8. Misfolded neural proteins linked to autism disorders
9. Researchers find function of proteins that can enhance the progression of viruses and cancer cells
10. Hydrophobic proteins: Potential biomarkers for colorectal cancer
11. Expression of certain transporter proteins may predict resistance to drug therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... , ... Goodcents Deli Fresh Subs today announced the opening of a new ... St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by ... locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... , ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an ... 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ... Denmark in 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in ...
(Date:6/23/2017)... TX (PRWEB) , ... June 23, 2017 , ... All-Star ... to residential and business clients throughout eastern Texas, is announcing the launch of a ... , Recent breast cancer statistics in the United States reveal that an estimated 252, ...
(Date:6/22/2017)... ... 22, 2017 , ... Plastic Surgery Associates is proud to report that founding ... year, research and information firm, Castle Connolly, releases their list of the most notable ... the 3rd time that Dr. Canales has been recognized by Castle Connolly. ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: